Kreyenbuhl J - Search Results

1

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT). Buchanan RW, et al. Among authors: kreyenbuhl j. Schizophr Bull. 2010 Jan;36(1):71-93. doi: 10.1093/schbul/sbp116. Epub 2009 Dec 2. Schizophr Bull. 2010. PMID: 19955390 Free PMC article. Review.

2

Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials.

McMahon RP, Kelly DL, Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. McMahon RP, et al. Among authors: kreyenbuhl j. Neuropsychopharmacology. 2002 Apr;26(4):537-45. doi: 10.1016/S0893-133X(01)00387-6. Neuropsychopharmacology. 2002. PMID: 11927178

3

Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia.

Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. Buchanan RW, et al. Among authors: kreyenbuhl j. Am J Psychiatry. 2002 Jun;159(6):1035-43. doi: 10.1176/appi.ajp.159.6.1035. Am J Psychiatry. 2002. PMID: 12042194

4

The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome.

Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. Buchanan RW, et al. Among authors: kreyenbuhl j. Schizophr Bull. 2002;28(1):63-73. doi: 10.1093/oxfordjournals.schbul.a006927. Schizophr Bull. 2002. PMID: 12047023

5

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW. Koro CE, et al. Among authors: kreyenbuhl j. BMJ. 2002 Aug 3;325(7358):243. doi: 10.1136/bmj.325.7358.243. BMJ. 2002. PMID: 12153919 Free PMC article.

6

Circumstances of suicide among individuals with schizophrenia.

Kreyenbuhl JA, Kelly DL, Conley RR. Kreyenbuhl JA, et al. Schizophr Res. 2002 Dec 1;58(2-3):253-61. doi: 10.1016/s0920-9964(01)00379-6. Schizophr Res. 2002. PMID: 12409166

7

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW. Koro CE, et al. Among authors: kreyenbuhl j. Arch Gen Psychiatry. 2002 Nov;59(11):1021-6. doi: 10.1001/archpsyc.59.11.1021. Arch Gen Psychiatry. 2002. PMID: 12418935

8

Racial disparity in the pharmacological management of schizophrenia.

Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Kreyenbuhl J, et al. Schizophr Bull. 2003;29(2):183-93. doi: 10.1093/oxfordjournals.schbul.a006996. Schizophr Bull. 2003. PMID: 14552495

9

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.

Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Kelly DL, et al. Among authors: kreyenbuhl j. J Clin Psychiatry. 2003 Sep;64(9):1133-4. doi: 10.4088/jcp.v64n0921f. J Clin Psychiatry. 2003. PMID: 14628994 No abstract available.

10

Evidence-based treatment for schizophrenia.

Lehman AF, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden L, Kreyenbuhl J. Lehman AF, et al. Among authors: kreyenbuhl j. Psychiatr Clin North Am. 2003 Dec;26(4):939-54. doi: 10.1016/s0193-953x(03)00070-4. Psychiatr Clin North Am. 2003. PMID: 14711129 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

94 results

Search Page